Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.

Published: 24 February 2017

Recent Videos: ASCO GU Conference Coverage

video

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added ...

video

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains what physicians need to know ...

video

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

Dr. Shore, MD, Director, Carolina Urologic Research Center, details how CHAARTED and STAMPEDE influenced his treatment of metastatic hormone sensitive ...

video

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses intriguing data and presentations from ASCO GU.

video

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, gives information ...

video

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, gives his views on which specific drugs have ...

video

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on how ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains how the treatment of advanced prostate cancer ...

video

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way ...

video

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has ...

video

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.

video

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, relays the ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, shares his thoughts on how to integrate multiple ...

video

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, briefly relays the data and conclusions from ...

video

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, describes the biggest challenges facing patients and providers in the diagnosis ...

video

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, explains his views on why some bladder cancer ...

video

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, relays the top line results for the ...

video

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, provides his ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains which metastatic castration-resistant prostate cancer patients, are ...

video

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center on how CHAARTED and STAMPEDE impacted her ...

video

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on how immunotherapies are being integrated into renal cell carcinoma ...

video

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains how genomics are helping physicians ...

video

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, discusses what physicians ...

video

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

Dr. Shore, MD, Director, Carolina Urologic Research Center, on which metastatic castration-resistant prostate cancer patients should receive chemotherapy.

video

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, explains the impact his data, as presented in “General ...

video

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, explains the types of metastatic renal cell carcinoma patients that should ...

video

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, discusses the ...

video

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, opines on whether non-invasive imaging is ready for ...

video

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, discusses how the surgery, radiation, and active ...

video

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, explains how ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, weighs in on if genetic testing for BRCA1 ...

video

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, on the fit of chemotherapy for prostate ...

video

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on the optimistic view of using immunotherapies to treat renal ...

video

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, provides his ...

video

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...

video

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his view on how side effects ...

video

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, weighs in ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, discusses how CHAARTED and STAMPEDE influences his treatment ...

video

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, provides her opinion on how a commercial ...

video

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, discusses the results of his ASCO GU poster session.

video

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, describes how genomics are changing the ...

video

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, reveals highlights from ...

video

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

Dr. Shore, MD, Director, Carolina Urologic Research Center, describes where chemotherapy fits into treatment for prostate cancer.

video

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses treatment trends in urology for 2017 and beyond.

video

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, provides insight into how immunotherapies are being integrated into renal cell ...

video

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, describes the ...

video

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...

video

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his thoughts on the most exciting ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers feedback on if immunotherapy will be added ...

video

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, offers key takeaways and highlights from ...

video

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, offers thoughts on ...

video

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, offers his opinion on whether or not BRCA1 and BRCA2 genetic testing ...

video

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

Dr. Holzbeierlein, Associate Professor of Urology, University of Kansas Hospital, describes the data and conclusions he presented in “General Session ...

video

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

Dr. Shore, MD, Director, Carolina Urologic Research Center, explains how an AR-V7 commercial test will affect initial and subsequent choice ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

Nicholas J. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on the impact a commercial AR-V7 test ...

video

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

Dr. Vaishampayan, Department of Oncology, Karmanos Cancer Institute, discusses the most intriguing research presented at ASCO GU.

video

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, weighs in ...

video

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses the impact genomics have in the way ...

video

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on where chemotherapy fits into treatment for prostate cancer

video

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

David J. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, relays the importance of genomics to help ...

video

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

Dr. Hamdy, Head of the Nuffield Department of Surgery, University of Oxford, explains how the ProtecT study was designed.

video

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

Dr. Den, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on which topics ...

video

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

Dr. Aparicio, Associate Professor, The University of Texas MD Anderson Cancer Center, provides insight into who the right metastatic castration-resistant ...

video

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

Dr. Lalani, Medical Oncology, Dana Farber Cancer Institute, on the most intriguing research presentations here at ASCO GU.

video

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

Dr. Jonasch, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, ...

video

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning ...

video

Using new therapies earlier in prostate cancer may returns better results

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better ...

video

Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium

Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco.

video

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in ...

video

Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC - Dr. Walter Stadler

Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors ...

video

Avelumab tolerable for patients according to JAVELIN Solid Tumor phase Ib trial

Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN ...

video

Evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone

Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone ...

Related Videos

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer